POLBF (Poolbeg Pharma) Total Receivables: $0.49 Mil (As of Dec. 2025)


What is Poolbeg Pharma Total Receivables?

Poolbeg Pharma POLBF Total Receivables is $0.49 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Poolbeg Pharma's Total Receivables for the quarter that ended in Dec. 2025 was $0.49 Mil.

Poolbeg Pharma Total Receivables Related Terms

Poolbeg Pharma Total Receivables Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Total Receivables Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
0.61 1.07 0.89 0.66 0.49

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only 0.89 0.91 0.66 0.62 0.49

Poolbeg Pharma Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.49 Mil mean?
Poolbeg Pharma (POLBF) has a Total Receivables of $0.49 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's Total Receivables too high?
Poolbeg Pharma's current Total Receivables is $0.49 Mil.
How does Poolbeg Pharma's Total Receivables compare to VRTX and REGN?
Poolbeg Pharma's Total Receivables of $0.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current Total Receivables is $0.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Total Receivables of $0.49 Mil. The current Total Receivables is $0.49 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Total Receivables is $0.49 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.